drugset / Trial / NCT00626002
Open Label Continuation Study in Moderate to Severe Psoriasis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
Timeline
- Start
- 2008-02
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | briakinumab | Monoclonal antibody | 100 mg | Subcutaneous |